For U.S. Healthcare Professionals Only
Indications
KRAZATI® (adagrasib), as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial.
KRAZATI® (adagrasib) in combination with cetuximab is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Full Prescribing Information
Patient Information
BMS Connect
Patient Site
SWITCH INDICATIONS
Identifying Patients With Possible KRAS G12C Mutations
About KRAS G12C
View MOA
Dosing Details